XML 23 R73.htm IDEA: XBRL DOCUMENT v2.3.0.15
Acquisitions (Details Textual) (USD $)
In Thousands, unless otherwise specified
12 Months Ended12 Months Ended12 Months Ended
Jun. 30, 2010
Sep. 30, 2011
Medical [Member]
Carmel Pharma [Member]
Sep. 30, 2011
Carmel Pharma [Member]
Mar. 17, 2011
Biosciences [Member]
Accuri [Member]
Sep. 30, 2011
Accuri [Member]
Mar. 17, 2011
Accuri [Member]
Mar. 17, 2011
Personal flow cytomery technology [Member]
Nov. 19, 2009
Diagnostics [Member]
Handy Lab [Member]
Sep. 30, 2011
Handy Lab [Member]
Nov. 19, 2009
Handy Lab [Member]
Nov. 19, 2009
Platform Technology [Member]
Nov. 19, 2009
Jaguar Plus Technology [Member]
Acquisitions (Textuals) [Abstract]            
Percentage of outstanding shares acquired  100.00%  100.00%   100.00%  
Acquisition-date fair value of consideration transferred net of in cash acquired  $ 287,111 $ 204,970$ 204,970  $ 277,610$ 277,610  
Cash acquired in acquisition  5,047  3,112      
Research and development asset    42,300 42,300 169,000169,00026,000143,000
Amount reclassified from initial IPR&D valued26,000           
Goodwill allocated to business segments 145,386145,38694,29994,299  147,456147,456   
Acquisition related costs in the current Period  5,250 900   2,500   
Portion of goodwill expected to be deductible for tax purposes  0 0   0   
Unamortized balance at acquisition date         2,854  
Gain or loss from acquisition         $ 0  
Terms related to initial payment for exclusive distribution rights (in years)        12 years   
Useful life assigned to amount reclassified from IPR&D to Core and Dev.Tech        20 years